These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

615 related articles for article (PubMed ID: 20195654)

  • 1. Cross-protection against influenza virus infection by intranasal administration of M2-based vaccine with chitosan as an adjuvant.
    Sui Z; Chen Q; Wu R; Zhang H; Zheng M; Wang H; Chen Z
    Arch Virol; 2010 Apr; 155(4):535-44. PubMed ID: 20195654
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cross-protection against influenza virus infection by intranasal administration of M1-based vaccine with chitosan as an adjuvant.
    Sui Z; Chen Q; Fang F; Zheng M; Chen Z
    Vaccine; 2010 Nov; 28(48):7690-8. PubMed ID: 20870054
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A live bivalent influenza vaccine based on a H9N2 virus strain.
    Wu R; Guan Y; Yang Z; Chen J; Wang H; Chen Q; Sui Z; Fang F; Chen Z
    Vaccine; 2010 Jan; 28(3):673-80. PubMed ID: 19892041
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of cross-protective immunity against influenza A virus H5N1 by an intranasal vaccine with extracts of mushroom mycelia.
    Ichinohe T; Ainai A; Nakamura T; Akiyama Y; Maeyama J; Odagiri T; Tashiro M; Takahashi H; Sawa H; Tamura S; Chiba J; Kurata T; Sata T; Hasegawa H
    J Med Virol; 2010 Jan; 82(1):128-37. PubMed ID: 19950232
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protection against multiple influenza A virus subtypes by intranasal administration of recombinant nucleoprotein.
    Guo L; Zheng M; Ding Y; Li D; Yang Z; Wang H; Chen Q; Sui Z; Fang F; Chen Z
    Arch Virol; 2010 Nov; 155(11):1765-75. PubMed ID: 20652335
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heterosubtypic protective immunity against widely divergent influenza subtypes induced by fusion protein 4sM2 in BALB/c mice.
    Chowdhury MY; Seo SK; Moon HJ; Talactac MR; Kim JH; Park ME; Son HY; Lee JS; Kim CJ
    Virol J; 2014 Feb; 11():21. PubMed ID: 24502341
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heterosubtypic immunity to influenza mediated by liposome adjuvanted H5N1 recombinant protein vaccines.
    Thueng-in K; Maneewatch S; Srimanote P; Songserm T; Tapchaisri P; Sookrung N; Tongtawe P; Channarong S; Chaicumpa W
    Vaccine; 2010 Sep; 28(41):6765-77. PubMed ID: 20688037
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protection against H1, H5, H6 and H9 influenza A infection with liposomal matrix 2 epitope vaccines.
    Ernst WA; Kim HJ; Tumpey TM; Jansen AD; Tai W; Cramer DV; Adler-Moore JP; Fujii G
    Vaccine; 2006 Jun; 24(24):5158-68. PubMed ID: 16713037
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.
    Prabakaran M; Velumani S; He F; Karuppannan AK; Geng GY; Yin LK; Kwang J
    Virology; 2008 Oct; 380(2):412-20. PubMed ID: 18786689
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A live attenuated H1N1 M1 mutant provides broad cross-protection against influenza A viruses, including highly pathogenic A/Vietnam/1203/2004, in mice.
    Xie H; Liu TM; Lu X; Wu Z; Belser JA; Katz JM; Tumpey TM; Ye Z
    J Infect Dis; 2009 Dec; 200(12):1874-83. PubMed ID: 19909080
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protection against avian influenza H9N2 virus challenge by immunization with hemagglutinin- or neuraminidase-expressing DNA in BALB/c mice.
    Qiu M; Fang F; Chen Y; Wang H; Chen Q; Chang H; Wang F; Wang H; Zhang R; Chen Z
    Biochem Biophys Res Commun; 2006 May; 343(4):1124-31. PubMed ID: 16580631
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inactivated and adjuvanted whole-virion clade 2.3.4 H5N1 pre-pandemic influenza vaccine possesses broad protective efficacy against infection by heterologous clades of highly pathogenic H5N1 avian influenza virus in mice.
    Harada Y; Ninomiya-Mori A; Takahashi Y; Shirakura M; Kishida N; Kageyama T; Tada Y; Tashiro M; Odagiri T
    Vaccine; 2011 Oct; 29(46):8330-7. PubMed ID: 21911027
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of inactivated vaccine against H5N1 influenza virus infection in mice with type 1 diabetes.
    Wu J; Zhang F; Fang F; Chang H; Wang F; Yang Z; Sun B; Chen Z
    Vaccine; 2010 Mar; 28(15):2775-81. PubMed ID: 20117261
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction of protection against divergent H5N1 influenza viruses using a recombinant fusion protein linking influenza M2e to Onchocerca volvulus activation associated protein-1 (ASP-1) adjuvant.
    Zhao G; Du L; Xiao W; Sun S; Lin Y; Chen M; Kou Z; He Y; Lustigman S; Jiang S; Zheng BJ; Zhou Y
    Vaccine; 2010 Oct; 28(44):7233-40. PubMed ID: 20732469
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bacterium-like particles supplemented with inactivated influenza antigen induce cross-protective influenza-specific antibody responses through intranasal administration.
    de Haan A; Haijema BJ; Voorn P; Meijerhof T; van Roosmalen ML; Leenhouts K
    Vaccine; 2012 Jul; 30(32):4884-91. PubMed ID: 22537989
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intranasal immunization with live attenuated influenza vaccine plus chitosan as an adjuvant protects mice against homologous and heterologous virus challenge.
    Wang X; Zhang W; Liu F; Zheng M; Zheng D; Zhang T; Yi Y; Ding Y; Luo J; Dai C; Wang H; Sun B; Chen Z
    Arch Virol; 2012 Aug; 157(8):1451-61. PubMed ID: 22552485
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Generation and evaluation of the trivalent inactivated reassortant vaccine using human, avian, and swine influenza A viruses.
    Du N; Li W; Li Y; Liu S; Sui Y; Qu Z; Wang Y; Du Y; Xu B
    Vaccine; 2008 Jun; 26(23):2912-8. PubMed ID: 18448208
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PolyI:polyC12U adjuvant-combined intranasal vaccine protects mice against highly pathogenic H5N1 influenza virus variants.
    Ichinohe T; Ainai A; Tashiro M; Sata T; Hasegawa H
    Vaccine; 2009 Oct; 27(45):6276-9. PubMed ID: 19840660
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effective small interfering RNAs targeting matrix and nucleocapsid protein gene inhibit influenza A virus replication in cells and mice.
    Zhou H; Jin M; Yu Z; Xu X; Peng Y; Wu H; Liu J; Liu H; Cao S; Chen H
    Antiviral Res; 2007 Nov; 76(2):186-93. PubMed ID: 17719657
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cross-protection against influenza virus infection by intranasal administration of nucleoprotein-based vaccine with compound 48/80 adjuvant.
    Zheng M; Liu F; Shen Y; Wang S; Xu W; Fang F; Sun B; Xie Z; Chen Z
    Hum Vaccin Immunother; 2015; 11(2):397-406. PubMed ID: 25607884
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.